Geode Capital Management
RARE icon

Geode Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Geode Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.8M Buy
1,849,391
+11,183
+0.6% +$252K ﹤0.01% 1637
2025
Q4 		$42.3M Buy
1,838,208
+257,701
+16% +$8.47M ﹤0.01% 1595
2025
Q3 		$47.6M Sell
1,580,507
-132,424
-8% -$3.97M ﹤0.01% 1492
2025
Q2 		$62.3M Buy
1,712,931
+66,394
+4% +$2.39M ﹤0.01% 1310
2025
Q1 		$59.6M Buy
1,646,537
+83,747
+5% +$3.48M ﹤0.01% 1276
2024
Q4 		$65.8M Sell
1,562,790
-8,291
-0.5% -$411K 0.01% 1255
2024
Q3 		$87.3M Buy
1,571,081
+65,623
+4% +$3.34M 0.01% 1077
2024
Q2 		$61.9M Buy
1,505,458
+165,632
+12% +$7.07M 0.01% 1211
2024
Q1 		$62.6M Buy
1,339,826
+56,204
+4% +$2.65M 0.01% 1198
2023
Q4 		$61.4M Buy
1,283,622
+200,335
+18% +$7.77M 0.01% 1213
2023
Q3 		$38.6M Buy
1,083,287
+22,674
+2% +$898K ﹤0.01% 1399
2023
Q2 		$48.9M Buy
1,060,613
+45,973
+5% +$2.13M 0.01% 1265
2023
Q1 		$40.7M Buy
1,014,640
+31,610
+3% +$1.36M 0.01% 1335
2022
Q4 		$45.5M Buy
983,030
+58,153
+6% +$2.29M 0.01% 1219
2022
Q3 		$38.3M Buy
924,877
+16,164
+2% +$831K 0.01% 1277
2022
Q2 		$54.2M Buy
908,713
+5,813
+0.6% +$358K 0.01% 1052
2022
Q1 		$65.6M Buy
902,900
+25,944
+3% +$1.81M 0.01% 1055
2021
Q4 		$73.7M Buy
876,956
+30,889
+4% +$2.51M 0.01% 1009
2021
Q3 		$76.3M Buy
846,067
+30,868
+4% +$2.79M 0.01% 969
2021
Q2 		$77.7M Sell
815,199
-261,334
-24% -$27.2M 0.01% 954
2021
Q1 		$123M Buy
1,076,533
+99,514
+10% +$13.5M 0.02% 663
2020
Q4 		$135M Buy
977,019
+118,222
+14% +$14M 0.02% 584
2020
Q3 		$70.6M Buy
858,797
+995
+0.1% +$82.5K 0.01% 747
2020
Q2 		$67.1M Buy
857,802
+40,827
+5% +$2.7M 0.01% 733
2020
Q1 		$36.3M Buy
816,975
+72,120
+10% +$3.74M 0.01% 933
2019
Q4 		$31.8M Buy
744,855
+13,176
+2% +$544K 0.01% 1244
2019
Q3 		$31.3M Buy
731,679
+7,390
+1% +$401K 0.01% 1172
2019
Q2 		$46M Buy
724,289
+53,043
+8% +$3.38M 0.01% 917
2019
Q1 		$46.6M Buy
671,246
+103,016
+18% +$5.89M 0.01% 879
2018
Q4 		$24.7M Buy
568,230
+63,118
+12% +$3.45M 0.01% 1141
2018
Q3 		$38.6M Buy
505,112
+25,598
+5% +$2.08M 0.01% 966
2018
Q2 		$36.9M Buy
479,514
+44,442
+10% +$2.87M 0.01% 939
2018
Q1 		$22.2M Buy
435,072
+71,882
+20% +$3.62M 0.01% 1190
2017
Q4 		$16.8M Sell
363,190
-419
-0.1% -$20.5K 0.01% 1388
2017
Q3 		$19.4M Buy
363,609
+15,370
+4% +$911K 0.01% 1264
2017
Q2 		$21.6M Buy
348,239
+14,515
+4% +$874K 0.01% 1118
2017
Q1 		$22.6M Buy
333,724
+34,956
+12% +$2.66M 0.01% 1049
2016
Q4 		$21M Buy
298,768
+24,529
+9% +$1.74M 0.01% 1053
2016
Q3 		$19.5M Buy
274,239
+11,018
+4% +$703K 0.01% 1026
2016
Q2 		$12.9M Buy
263,221
+5,508
+2% +$356K 0.01% 1243
2016
Q1 		$16.3K Buy
257,713
+9,987
+4% +$653K 0.01% 1046
2015
Q4 		$27.8M Buy
247,726
+10,287
+4% +$1.03M 0.02% 730
2015
Q3 		$22.9M Buy
237,439
+48,140
+25% +$5.51M 0.01% 811
2015
Q2 		$19.4M Buy
189,299
+49,450
+35% +$3.84M 0.01% 953
2015
Q1 		$8.68M Buy
139,849
+16,985
+14% +$943K 0.01% 1497
2014
Q4 		$5.39M Sell
122,864
-2,292
-2% -$105K ﹤0.01% 1765
2014
Q3 		$7.08M Buy
125,156
+88,416
+241% +$4.45M ﹤0.01% 1527
2014
Q2 		$1.65M Buy
36,740
+778
+2% +$32K ﹤0.01% 2499
2014
Q1 		$1.76M Buy
+35,962
New +$1.85M ﹤0.01% 2414

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management's RARE Position: Q1 2026 in Review

Geode Capital Management increased its Ultragenyx Pharmaceutical (RARE) stake by 0.61% in Q1 2026, buying an estimated $252K and bringing the position to 1,849,391 shares worth $38.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1637.

Geode Capital Management first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $135M in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Geode Capital Management held 1,849,391 shares of Ultragenyx Pharmaceutical worth $38.8M as of Q1 2026.
  • Geode Capital Management bought 11,183 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $252K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1637 holding.
  • Geode Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • Geode Capital Management's Ultragenyx Pharmaceutical position peaked at $135M in Q4 2020.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.